Argitalpenak (22) DIANA PAREDES RUIZ argitalpenak

2024

  1. Balancing risks and benefits in the use of hydroxychloroquine and glucocorticoids in systemic lupus erythematosus

    Expert Review of Clinical Immunology, Vol. 20, Núm. 4, pp. 359-373

  2. Clinical Presentation and Outcomes of Patients with Cancer-Associated Isolated Distal Deep Vein Thrombosis

    Journal of Clinical Oncology, Vol. 42, Núm. 5, pp. 529-537

  3. Elucidating the mechanisms and efficacy of antimalarial drugs in systemic lupus erythematosus

    Expert Opinion on Pharmacotherapy

  4. Methylprednisolone Pulses and Prolonged Remission in Systemic Lupus Erythematosus: A Propensity Score Analysis of the Longitudinal Lupus-Cruces-Bordeaux Inception Cohort

    Arthritis Care and Research, Vol. 76, Núm. 8, pp. 1132-1138

  5. Thrombotic antiphospholipid syndrome: From guidelines to clinical management

    Medicina Clinica, Vol. 163, pp. S22-S30

  6. Use of Glucocorticoids in SLE: A Clinical Approach

    Mediterranean Journal of Rheumatology, Vol. 35, pp. 342-353

2023

  1. A prognostic score to identify women at increased risk for abnormal uterine bleeding during anticoagulation for venous thromboembolism

    Thrombosis Update, Vol. 13

  2. Bilateral cervical masses

    Revue de Medecine Interne, Vol. 44, Núm. 6, pp. 311-313

  3. COVID-19–associated venous thromboembolism: risk of recurrence and major bleeding

    Research and Practice in Thrombosis and Haemostasis, Vol. 7, Núm. 7

  4. Cytomegalovirus reactivation in patients with immune-mediated gastritis

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 41, Núm. 5, pp. 298-300

  5. Multidisciplinary management in chronic myeloid leukemia improves cardiovascular risk measured by SCORE

    Frontiers in Pharmacology, Vol. 14

  6. Systemic lupus erythematosus and glucocorticoids: A never-ending story?

    Best Practice and Research: Clinical Rheumatology, Vol. 37, Núm. 4

  7. The value of the CHAP model for prediction of the bleeding risk in patients with unprovoked venous thromboembolism: Findings from the RIETE registry

    Thrombosis Research

  8. Venous thromboembolism characteristics, treatment and outcomes in young adults: findings from the Registro Informatizado de Enfermedad TromboEmbólica registry

    Journal of Thrombosis and Haemostasis, Vol. 21, Núm. 10, pp. 2811-2823

2022

  1. Clinical Differences and Outcomes of COVID-19 Associated Pulmonary Thromboembolism in Comparison with Non-COVID-19 Pulmonary Thromboembolism

    Journal of Clinical Medicine, Vol. 11, Núm. 20

  2. Clinical Features and Risk Factors for Mortality Among Long-term Care Facility Residents Hospitalized Due to COVID-19 in Spain

    Journals of Gerontology - Series A Biological Sciences and Medical Sciences, Vol. 77, Núm. 4, pp. E138-E147

  3. Incidence of venous thromboembolism in patients with non-hematological cancer admitted for COVID-19 at a third-level hospital in Madrid

    Journal of Thrombosis and Thrombolysis, Vol. 53, Núm. 2, pp. 471-478

  4. Influenza A-Associated In-Hospital Mortality in Very Older People: Does Inflammation Also Play a Role?

    Gerontology, Vol. 68, Núm. 7, pp. 780-788

  5. Inmunosupresión y sus complicaciones

    Manual de diagnóstico y terapéutica médica (Hospital Universitario 12 de Octubre), pp. 1427-1438

  6. The hazard of combining anticoagulants with antiplatelets in patients with venous thromboembolism: Findings from the RIETE registry

    Thrombosis Research